Finch Therapeutics Group, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Finch Therapeutics Group, Inc.
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.
Lupin links with Exeltis, Cresco and Macure to sell the NDM therapy in western and central Europe. Plus deals involving Cipla, GoApptiv, Takeda, Debiopharm, PharmaMar and TTY.
- Other Names / Subsidiaries
- Crestovo LLC
- Finch Therapeutics Inc.